NO20030588L - Anvendelse av 5HT4-reseptorantagonister ved profylakse eller behandling avvisse kardiovaskul¶re tilstander - Google Patents

Anvendelse av 5HT4-reseptorantagonister ved profylakse eller behandling avvisse kardiovaskul¶re tilstander

Info

Publication number
NO20030588L
NO20030588L NO20030588A NO20030588A NO20030588L NO 20030588 L NO20030588 L NO 20030588L NO 20030588 A NO20030588 A NO 20030588A NO 20030588 A NO20030588 A NO 20030588A NO 20030588 L NO20030588 L NO 20030588L
Authority
NO
Norway
Prior art keywords
prophylaxis
rejection
treatment
receptor antagonists
cardiovascular conditions
Prior art date
Application number
NO20030588A
Other languages
English (en)
Norwegian (no)
Other versions
NO20030588D0 (no
Inventor
Mireille Marguerite J Bonhomme
Antoine Michel Alain Bril
Bernard Emile Joseph Gout
Bela Rajiv Patel
Gillian Louise Shepherd
Neeta Balkrishan Amin
Bernard Enno Ilson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0019410A external-priority patent/GB0019410D0/en
Priority claimed from GB0019523A external-priority patent/GB0019523D0/en
Priority claimed from GB0019524A external-priority patent/GB0019524D0/en
Priority claimed from GB0118919A external-priority patent/GB0118919D0/en
Priority claimed from GB0119022A external-priority patent/GB0119022D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20030588D0 publication Critical patent/NO20030588D0/no
Publication of NO20030588L publication Critical patent/NO20030588L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20030588A 2000-08-07 2003-02-06 Anvendelse av 5HT4-reseptorantagonister ved profylakse eller behandling avvisse kardiovaskul¶re tilstander NO20030588L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0019410A GB0019410D0 (en) 2000-08-07 2000-08-07 Novel use
GB0019523A GB0019523D0 (en) 2000-08-08 2000-08-08 Novel use
GB0019524A GB0019524D0 (en) 2000-08-08 2000-08-08 Novel use
GB0118919A GB0118919D0 (en) 2001-08-02 2001-08-02 Novel use
GB0119022A GB0119022D0 (en) 2001-08-03 2001-08-03 Novel use
PCT/GB2001/003544 WO2002011766A2 (en) 2000-08-07 2001-08-07 Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation

Publications (2)

Publication Number Publication Date
NO20030588D0 NO20030588D0 (no) 2003-02-06
NO20030588L true NO20030588L (no) 2003-04-03

Family

ID=27515972

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030588A NO20030588L (no) 2000-08-07 2003-02-06 Anvendelse av 5HT4-reseptorantagonister ved profylakse eller behandling avvisse kardiovaskul¶re tilstander

Country Status (16)

Country Link
US (3) US20050032866A1 (pl)
EP (1) EP1311295A2 (pl)
JP (2) JP2004505930A (pl)
KR (1) KR20030027010A (pl)
CN (1) CN100413539C (pl)
AU (1) AU781276B2 (pl)
BR (1) BR0113073A (pl)
CA (1) CA2418904A1 (pl)
CZ (1) CZ2003366A3 (pl)
HU (1) HUP0303075A3 (pl)
IL (1) IL154279A0 (pl)
MX (1) MXPA03001210A (pl)
NO (1) NO20030588L (pl)
NZ (1) NZ524108A (pl)
PL (1) PL365048A1 (pl)
WO (1) WO2002011766A2 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1476136E (pt) * 2002-02-14 2006-10-31 Glaxo Group Ltd Composicao farmaceutica compreendendo n-((1-n-butil-4-piperidinil)metil)-3,4-di-hidro-2h-(1,3) oxazino (3,2-a) indole-10-carboxamida ou sal e processo de a obter compreendendo granulacao a seco.
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
EP2366431A1 (en) * 2010-03-19 2011-09-21 Universitätsklinikum Hamburg-Eppendorf Myeloperoxidase as a target in atrial fibrillation
JP6574773B2 (ja) 2014-07-30 2019-09-11 株式会社アエタスファルマ １，４−ベンゾチアゼピン−１−オキシド誘導体の光学異性体、及びそれを用いた医薬組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9009389D0 (en) * 1990-04-26 1990-06-20 Smith Kline French Lab Treatment
GB9103862D0 (en) * 1991-02-25 1991-04-10 Glaxo Group Ltd Chemical compounds
SG49153A1 (en) * 1991-09-12 1998-05-18 Smithkline Beecham Plc 5-HT4 receptor antagonists
MA22647A1 (fr) * 1991-09-14 1993-04-01 Smithkline Beecham Plc Procede de preparation d'un ester ou d'un amide d'un nouveau produit .
WO1993018036A1 (en) * 1992-03-12 1993-09-16 Smithkline Beecham Plc Condensed indole derivatives as 5ht4-receptor antagonists
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
MX9301837A (es) * 1992-03-31 1994-02-28 Glaxo Group Ltd Ureas y fenilcarbamatos substituidos, proceso para su preparacion y composicion farmaceutica que los comprende.
GB9206989D0 (en) * 1992-03-31 1992-05-13 Glaxo Group Ltd Chemical compounds
CA2133083A1 (en) * 1992-03-31 1993-10-14 Alexander W. Oxford Substituted phenylcarbamates and phenylureas, their preparation and their use as 5-ht antagonists
AU680004B2 (en) * 1993-05-26 1997-07-17 Syntex (U.S.A.) Inc. Novel 1-phenylalkanone 5-HT4 receptor ligands
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
JP3911297B2 (ja) * 1996-08-16 2007-05-09 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Ｎ―［（１―ｎブチル―４―ピペリジル）メチル］―３，４―ジヒドロ―２Ｈ―［１，３］オキサジノ［３，２―ａ］インドール―１０―カルボキシアミドおよび塩ならびに製造における中間体
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide

Also Published As

Publication number Publication date
CA2418904A1 (en) 2002-02-14
AU781276B2 (en) 2005-05-12
NO20030588D0 (no) 2003-02-06
KR20030027010A (ko) 2003-04-03
US20070015769A1 (en) 2007-01-18
CN1468112A (zh) 2004-01-14
US20080125422A1 (en) 2008-05-29
IL154279A0 (en) 2003-09-17
HUP0303075A2 (hu) 2003-12-29
HUP0303075A3 (en) 2007-03-28
AU7652901A (en) 2002-02-18
US20050032866A1 (en) 2005-02-10
MXPA03001210A (es) 2004-08-12
JP2004505930A (ja) 2004-02-26
CZ2003366A3 (en) 2004-04-14
NZ524108A (en) 2004-11-26
BR0113073A (pt) 2004-06-22
WO2002011766A2 (en) 2002-02-14
PL365048A1 (pl) 2004-12-27
EP1311295A2 (en) 2003-05-21
JP2007145869A (ja) 2007-06-14
WO2002011766A3 (en) 2002-08-01
CN100413539C (zh) 2008-08-27

Similar Documents

Publication Publication Date Title
NO20034169D0 (no) MCH-antagonister og deres anvendelse ved behandling av fedme
NO20013340L (no) Antagonister for TWEAK og for TWEAK-reseptor samt anvendelse derav ved behandling av immunologiske lidelser
DE60003148D1 (de) Bestimmung der Cachezeit
NO20024682D0 (no) Kombinert anvendelse av anti-cytokin-antistoff eller antagonister og anti-CD20 ved behandling av B-celle-lymfom
NO20014379L (no) Anvendelse av Xenon for behandling av Neurointoksikasjoner
ATE302185T1 (de) Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität
DE60037213D1 (de) Verwendung von Reinigungsgas
DK1231920T3 (da) Anvendelse af epinastin til behandling af allergisk rhinitis/conjunctivitis
EP1501357A4 (en) USE OF VEGF FOR THE TREATMENT OF BONE DEFECTS
DE60106607D1 (de) Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten
NO20014131D0 (no) Epitoper eller mimotoper avledet fra C-epsilon-3- eller C- epsilon-4-domener fra IgE, antagonister derav og deresterapeutiske anvendelser
ITMI20011351A0 (it) Gruppo di svuotamento per il recupero del residuo di fondo particolarmente in filtei essicatori essicatori e simili
HUP0104085A3 (en) Use of vasopressin antagonists for the preparation of pharmaceutical compositions treating pulmonary hypertension
NO20033443D0 (no) Anvendelse av CD-2-bindende midler ved behandling eller forebygging av hudlidelser
NO20030588D0 (no) Anvendelse av 5HT4-reseptorantagonister ved profylakse eller behandling avvisse kardiovaskul¶re tilstander
DE69915113D1 (de) 5ht1 rezeptor antagonisten und ihre verwendung für die behandlung von depression
NO20014130L (no) Epitoper eller mimotoper avledet fra C-<epsilon>2-domenet hos IgE, antagonister derav og deres terapeutiske anvendelser
ATE291916T1 (de) Verwendung von optisch reinem (-) norcisapride in der behandlung des reizdarmsyndroms
NO20033388D0 (no) Anvendelse av GAL3-reseptorantagonister ved behandling av depresjon og/eller angst samt forbindelser som er anvendelige ved slik behandling
NO20005386L (no) Anvendelse av NMDA-antagonister for behandling av irritabel tarmsyndrom
NO20020008L (no) Anvendelse av cortisol antagonister i behandling av hjertesvikt
ATE284870T1 (de) Antagonisten des vitronectin-receptors
NO20012093L (no) Behandling av massemöllekondensat med ozon
FR2877201B3 (fr) Dispositif pour l'installation et/ou l'utilisation de barres, notamment pour porte-serviette
NO20004142L (no) Ftalimidoarylpiperaziner som <alfa> 1A reseptorantagonister anvendelige ved behandling av benign prostatahyperplasi

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application